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ABSTRACT
Objective: It is well known that total cholesterol
becomes less of a risk factor or not at all for all-cause
and cardiovascular (CV) mortality with increasing age,
but as little is known as to whether low-density
lipoprotein cholesterol (LDL-C), one component of total
cholesterol, is associated with mortality in the elderly,
we decided to investigate this issue.
Setting, participants and outcome measures:
We sought PubMed for cohort studies, where LDL-C
had been investigated as a risk factor for all-cause and/
or CV mortality in individuals ≥60 years from the
general population.
Results: We identified 19 cohort studies including 30
cohorts with a total of 68 094 elderly people, where
all-cause mortality was recorded in 28 cohorts and CV
mortality in 9 cohorts. Inverse association between all-
cause mortality and LDL-C was seen in 16 cohorts (in
14 with statistical significance) representing 92% of
the number of participants, where this association was
recorded. In the rest, no association was found. In two
cohorts, CV mortality was highest in the lowest LDL-C
quartile and with statistical significance; in seven
cohorts, no association was found.
Conclusions: High LDL-C is inversely associated with
mortality in most people over 60 years. This finding is
inconsistent with the cholesterol hypothesis (ie, that
cholesterol, particularly LDL-C, is inherently
atherogenic). Since elderly people with high LDL-C live
as long or longer than those with low LDL-C, our
analysis provides reason to question the validity of the
cholesterol hypothesis. Moreover, our study provides
the rationale for a re-evaluation of guidelines
recommending pharmacological reduction of LDL-C in
the elderly as a component of cardiovascular disease
prevention strategies.
INTRODUCTION
Rationale
For decades, the mainstream view has been
that an elevated level of total cholesterol
(TC) is a primary cause of atherosclerosis
and cardiovascular disease (CVD). There are
several contradictions to this view, however.
No study of unselected people has found an
association between TC and degree of ath-
erosclerosis.1 Moreover, in most of the
Japanese epidemiological studies, high TC is
not a risk factor for stroke, and further, there
is an inverse association between TC and all-
cause mortality, irrespective of age and sex.2
In a recent meta-analysis performed by the
Prospective Studies Collaboration, there was
Strengths and limitations of this study
▪ This is the first systematic review of cohort
studies where low-density lipoprotein cholesterol
(LDL-C) has been analysed as a risk factor for
all-cause and/or cardiovascular mortality in
elderly people.
▪ Lack of an association or an inverse association
between LDL-C and mortality was present in all
studies.
▪ We may not have included studies where an
evaluation of LDL-C as a risk factor for mortality
was performed but where it was not mentioned
in the title or in the abstract.
▪ We may have overlooked relevant studies
because we have only searched PubMed.
▪ Minor errors may be present because some of
the authors may not have adjusted LDL-C by
appropriate risk factors.
▪ Some of the participants with high LDL-C may
have started statin treatment during the observa-
tion period and, in this way, may have added a
longer life to the group with high LDL-C and
some of them may have started with a diet able
to influence the risk of mortality.
▪ We may have overlooked a small number of rele-
vant studies because we only searched papers in
English.
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an association between TC and CV mortality in all ages
and in both sexes.3 However, even in this analysis, the
risk decreased with increasing age and became minimal
after the age of 80 years. Since atherosclerosis and CVD
are mainly diseases of the elderly, the cholesterol
hypothesis predicts that the association between CV mor-
tality and TC should be at least as strong in the elderly
as in young people. There may be a confounding inﬂu-
ence in these studies, however, because TC includes
high-density lipoprotein cholestrol (HDL-C), and mul-
tiple studies have shown that a high level of HDL-C is
associated with a lower risk of CVD.
Objectives
We examined the literature assessing low-density lipopro-
tein cholesterol (LDL-C) as a risk factor for mortality in
elderly people. Since the deﬁnition of CVD varies con-
siderably in the scientiﬁc literature, we have chosen to
focus on the association between LDL-C and all-cause
and CVD mortality, because mortality has the least risk
of bias among all outcome measures. If Goldstein and
Brown’s recent statement that LDL-C is ‘the essential
causative agent’ of CVD4 is correct, then we should ﬁnd
that LDL-C is a strong risk factor for mortality in elderly
people.
METHODS
Search strategy
UR and RS searched PubMed independently from
initial to 17 December 2015. The following keywords
were used: ‘lipoprotein AND (old OR elderly) AND
mortality NOT animal NOT trial’. We also retrieved the
references in the publications so as not to miss any rele-
vant studies. The search was limited to studies in
English.
Inclusion and exclusion criteria
All included studies should meet the following criteria: the
study should be a cohort study of people aged 60 years or
older selected randomly from the general population, or a
study where the authors had found no signiﬁcant differ-
ences between the participants and the source popula-
tion’s demographic characteristics. The studies should
include an initial assessment of LDL-C levels, the length of
the observation time and information about all-cause
and/or cardiovascular mortality at the end of follow-up.
The studies should also include information about the
association between LDL-C and all-cause and/or CVD
mortality. We excluded studies that did not represent the
general population (eg, case–control studies; case reports;
studies that included patients only); studies where data
about elderly people were not given separately, and studies
without multivariate correction for the association
between LDL-C and all-cause and/or CV mortality. We
accepted studies where the authors had excluded patients
with serious diseases or individuals who had died during
the ﬁrst year.
Study selection, data items and extraction
Studies where the title or abstract indicated that they
might include LDL-C data of elderly people, were read
in full, and the relevant data were extracted by at least
three of the authors, for example, year of publication,
total number of participants, sex, length of observation
time, exclusion criteria, LDL-C measured at the start
and the association between initial LDL-C and risk of all-
cause and/or CV mortality at follow-up. When more
than one adjusted HR was reported, the HR with the
most fully adjusted model was selected.
Quality assessment
The design of the study satisﬁes almost all points of reli-
ability and validity according to the Newcastle Ottawa
Scale as regards selection, comparability and exposure.5
Thus, all studies represented elderly people only; ascer-
tainness of exposure (eg, measurement of LDL-C) was
present in all studies, and outcome was unknown at the
start. It can be questioned if all of the studies repre-
sented the general population because, as shown below,
in some of them various types of disease groups were
excluded.
RESULTS
Study selection
Our search gave 2894 hits. We excluded 160 studies,
which were not in English, and 2452 studies because,
judged from the abstract, it was obvious that they were
irrelevant.
The rest of the papers were read in full; 263 of these
studies were excluded for the following reasons: (1) the
participants did not represent the general population;
(2) LDL-C was not measured at the start; (3) follow-up
information was not given for the elderly separately; or
(4) no information was present about mortality during
the observation period (ﬁgure 1). One of the studies6
was excluded because it included the same individuals
as in a previous study.7
Study characteristics
The remaining 19 studies including 30 cohorts with a
total of 68 094 participants met the inclusion criteria
(ﬁgure 1). All-cause mortality was recorded in 28
cohorts. In 16 of these cohorts (representing 92% of the
individuals), the association was inverse and with statis-
tical signiﬁcance in 14; in 1 of the cohorts, the associ-
ation was mirror-J-formed with the lowest risk in the
highest quartile; in the rest of the papers, no association
was found. CV mortality was recorded in nine cohorts;
in one of them, the association was almost U-shaped
with the lowest risk in the highest quartile (curvilinear
ﬁt: p=0.001); in one of them, the association was
mirror-J-formed and also with the lowest risk in the
highest quartile (curvilinear ﬁt: p=0.03); in the other
seven cohorts, no association was found (table 1).
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Risk of bias across studies
One explanation for the increased risk of mortality
among people with low cholesterol is that serious dis-
eases may lower cholesterol soon before death occurs.
Evidence to support this hypothesis may be obtained
from 10 of the studies in which no exclusions were
made for individuals with terminal illnesses. However, in
four of the studies, participants with a terminal illness or
who had died during the ﬁrst observation year were
excluded. In one of those studies,8 LDL-C was not asso-
ciated with all-cause mortality; in the three others,16 20 24
which included more than 70% of the total number of
participants in our review, LDL-C was inversely asso-
ciated with all-cause mortality and with statistical signiﬁ-
cance. Thus, there is little support for the hypothesis
that our analysis is biased by end of life changes in
LDL-C levels.
It is also potentially relevant that all studies did not
correct for the same risk factors, and some of them did
not inform the reader about which risk factors they cor-
rected for. However, taking all studies together, 50 differ-
ent risk factors were corrected for in the Cox analyses
(table 2).
It is worth considering that some of the participants
with high LDL-C may have started statin treatment
during the observation period. Such treatment may have
increased the lifespan for the group with high LDL-C.
However, any beneﬁcial effects of statins on mortality
would have been minimal because most statin trials have
had little effect on CVD and all-cause mortality, with a
maximum reduction of mortality of two percentage
points. It is therefore relevant that the 4-year mortality
among those with the highest LDL-C in the included
cohorts was up to 36% lower than among those with the
Figure 1 Flow Chart. CV,
cardiovascular; LDL-C,
low-density lipoprotein
cholesterol.
Ravnskov U, et al. BMJ Open 2016;6:e010401. doi:10.1136/bmjopen-2015-010401 3
Open Access
group.bmj.com on January 4, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
Table 1 Association between LDL-C and all-cause mortality and CVD mortality, respectively, in 19 studies including 30 cohorts with 68 094 individuals from the general population above the age of
60 years
Authors Race if indicated Sex N
Age;
years
Obs.
Years
All-cause mortality
LDL-C tertiles or
quartiles (HRs)
CV mortality Exclusion criteriaI II III IV
Zimetbaum et al8 MF 350 75–85 6, 3 No association NI Terminal illness, dementia
Kronmal et al9 MF 747 66–75 10 No association NI None
176 >75 No association NI
Räihä et al10 MF 347 ≥65 11 NI No association Living in an institution
Fried et al7 MF 5201 ≥65 4.8 1.0 ? ? 0.66 (significant) NI Wheelchair user; cancer treatment
Chyou and Eaker11 M 367 ≥65 8–10 No association NI None
F 622 No association
Weverling-Rijnsburger et al12 MF 599 ≥85 4 1.0 0.57 0.71
p for trend*
No association None
Schupf et al13 MF 2277 ≥65 3 1.0 0.79 0.63 0.53
p for trend**
NI Dementia
Tikhonoff et al14 M 1233 ≥65 11, 1 Mirror-J-formed association with the highest risk
in the lowest quartile
Almost U-formed association
with the highest risk in the
lowest quartile*
Dementia
F 1887 Inverse association* Mirror-J-formed association
with the highest risk in the
lowest quartile*
Störk et al15 M 403 >70 4 No association No association None
Akerblom et al16
Caucasians MF 705 ≥65 3.5 1.0 0.89 0.72 0.56* NI Dementia, first year deaths
African-Americans MF 797 1.0 0.79 0.58 0.53*
Hispanics MF 1054 1.0 0.79 0.79 0.71
Upmeier et al17 MF 1032 70 12 No association No association None
Nilsson et al18 M 210 75 10 No association NI None
F 222 No association
Werle et al19 MF 187 ≥80 8, 7 No association No association None
Bathum et al20† M 13 733 60–70 1–9 1.0 0.67*** 0.49*** 0.45*** NI Terminal disease, CVD, diabetes,
patients with a prescription of
statin during the last year before test date
7493 ≥70 1.0 0.71*** 0.60*** 0.52***
F 14 298 60–70 1.0 0.56*** 0.45*** 0.47***
9142 ≥70 1.0 0.66*** 0.52*** 0.46***
Linna et al21 MF 1260 ≥64 10 Inverse association** NI None
Jacobs et al22 MF 512 78–85 8 No association NI None
702 85–90 5 No association
Takata et al23 MF 207 85 10 Survivors 3.2 mmol/L; non-survivors:
2.9 mmol/L**
No association None
Lv et al24 M 266 ≥80 3 1.0 0.67 0.43 0.41* NI First year deaths
F 596 1.0 0.69* 0.57** 0.59*
MF 1.0 0.72* 0.59** 0.60*
Blekkenhorst et al25 F 1469 ≥70 10 NI No association None
In the study by Fried et al, degree of significance was not reported.
*p<0.05; **p<0.01; ***p<0.001.
†HR for 7415 men and 8314 women on statin treatment was 0.63 and 0.61, respectively.
F, females; M, males; NI, no information.
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lowest LDL-C. Furthermore, in the largest study20 that
included about two-thirds of the total number of partici-
pants in our study, the risk was lower among those with
the highest LDL-C than among those on statin treatment.
It is also possible that those with the highest LDL-C
were put on a different diet than those with low LDL-C.
However, this potential bias in mortality outcomes
could have gone in both directions. Some of the indivi-
duals with high LDL-C may have followed the ofﬁcial
dietary guidelines and exchanged saturated fat with
vegetable oils rich in linoleic acid. In a recent study,
the authors reported that among participants who were
older than 65 at baseline, a 30 mg/dL decrease in
serum cholesterol was associated with a higher risk of
death (HR 1.35, 95% CI 1.18 to 1.54).26 If applied to
the general population, this ﬁnding suggests that the
conventional dietary treatment for high cholesterol
with vegetable oil replacing saturated fat may actually
increase mortality in those individuals with high
LDL-C. Thus, the lack of an association between LDL-C
and mortality may have been even stronger than
reported since the dietary intervention may have been
counterproductive.
Finally, it is potentially relevant that we limited our litera-
ture search to PubMed. In preliminary searches with
PubMed, OVID and EMBASE, we identiﬁed 17 relevant
studies in PubMed, but only 2 in OVID and EMBASE, and
these 2 studies were found in PubMed as well. Therefore,
it is highly unlikely that there are studies with ﬁndings with
divergent results from those we have reported here, as all
of them reported either no association or an inverse asso-
ciation between LDL-C and mortality.
DISCUSSION
Assessments of the association between serum cholesterol
and mortality have been studied for decades, and exten-
sive research has shown a weak association between total
cholesterol and mortality in the elderly; several studies
have even shown an inverse association. It is therefore sur-
prising that there is an absence of a review of the litera-
ture on mortality and levels of LDL-C, which is routinely
Table 2 Factors corrected for in the multifactorial analyses of each study
Authors Factors adjusted for
Zimetbaum et al Age, smoking, health self-rating, BMI, BP, diabetes, MI and IQ.
Kronmal et al Age, sex, BP, BMI, BMI squared, smoking.
Räihä et al Age, sex, smoking, alcohol use, BMI, CHD, BP and diabetes.
Fried et al Race, height, hip and waist circumference, BMI, smoking, diastolic BP, antihypertensive and
lipid-lowering treatment, TC, HDL-C, TG, diabetes, fasting insulin, factor VII and VIII, serum
potassium and uric acid, asthma, emphysema, angina, MI, stroke, claudication, arthritis, renal
disease, cancer, hearing and visual impairment, FEV, mitral stenosis and regurgitation, carotid
stenosis
Chyou and Eaker Age, sex, CHD, stroke, cancer, diabetes, BP, BMI, smoking, alcohol consumption
Weverling-Rijnsburger
et al
Comorbidities, BMI, use of β-blocking agents, thyroid dysfunction
Schupf et al Age, sex, ethnic group, BMI, level of education, APOE genotype, diabetes, heart disease, stroke,
cancer, smoking
Tikhonoff et al Age, BP, pulse rate, BMI, CV events, smoking, alcohol intake, diabetes, serum creatinine and uric
acid.
Störk et al Cox regression analysis. No details
Akerblom et al Age, sex, education, BMI, APOE genotype, heart disease, BP, diabetes, stroke, dementia,
smoking.
Upmeier et al Gender, BMI, smoking, angina pectoris, stroke, diabetes, hypertension, cancer
Nilsson et al BMI, smoking, non-HDL-C, TG, BP, diabetes, previous MI
Werle et al Factors that showed a trend for association in the univariate analyses, well-known risk factors for
total mortality or cardiovascular mortality.
Bathum et al Cox regression analysis. No details
Linna et al Age, sex, BMI, smoking, BP, diabetes
Jacobs et al Statin treatment, sex, CHD, BP, neoplasm, self-rated health, smoking, albumin, BMI, triglycerides.
Takata et al Sex, smoking, alcohol intake, stroke, heart disease, serum albumin, BMI, systolic BP
Lv et al 2015 Age, sex, marital status, smoking, alcohol drinking, tea drinking, central obesity, cognitive
impairment, daily activity, blindness, anaemia, BT, diabetes, CKD, HDL-C
Blekkenhorst et al Age, BMI, physical activity, renal function, smoking, diabetes, CVD, low-dose aspirin,
antihypertensive and statin medication, energy intake, SFA
In studies not corrected for age, all participants were of the same age.
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CKD, chronic kidney disease; CRP, C reactive protein; CVD,
cardiovascular disease; FEV, forced expiratory volume; HDL-C, high-density lipoprotein cholesterol; IMT, intima-media thickness; MI,
myocardial infarction; SFA, superficial femoral artery; TG, tryglicerides.
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referred to as a causal agent in producing CVD4 and is a
target of pharmacological treatment of CVD.
Our literature review has revealed either a lack of an
association or an inverse association between LDL-C and
mortality among people older than 60 years. In almost
80% of the total number of individuals, LDL-C was
inversely associated with all-cause mortality and with stat-
istical signiﬁcance.
These ﬁndings provide a paradoxical contradiction to
the cholesterol hypothesis. As atherosclerosis starts
mainly in middle-aged people and becomes more pro-
nounced with increasing age, the cholesterol hypothesis
would predict that there should be a cumulative athero-
sclerotic burden, which would be expressed as greater
CVD and all-cause mortality, in elderly people with high
LDL-C levels.
Our results raise several relevant questions for future
research. Why is high TC a risk factor for CVD in the
young and middle-aged, but not in elderly people? Why
does a subset of elderly people with high LDL-C live
longer than people with low LDL-C? If high LDL-C is
potentially beneﬁcial for the elderly, then why does
cholesterol-lowering treatment lower the risk of cardio-
vascular mortality? In the following we have tried to
address some of these questions.
Inverse causation
A common argument to explain why low lipid values
are associated with an increased mortality is inverse
causation, meaning that serious diseases cause low
cholesterol. However, this is not a likely explanation,
because in ﬁve of the studies in table 1 terminal
disease and mortality during the ﬁrst years of observa-
tion were excluded. In spite of that, three of them
showed that the highest mortality was seen among
those with the lowest initial LDL-C with statistical
signiﬁcance.18 20 24
Is high LDL-C beneficial?
One hypothesis to address the inverse association
between LDL-C and mortality is that low LDL-C
increases susceptibility to fatal diseases. Support for this
hypothesis is provided by animal and laboratory experi-
ments from more than a dozen research groups which
have shown that LDL binds to and inactivates a broad
range of microorganisms and their toxic products.27
Diseases caused or aggravated by microorganisms may
therefore occur more often in people with low choles-
terol, as observed in many studies.28 In a meta-analysis of
19 cohort studies, for instance, performed by the
National Heart, Lung and Blood Institute and including
68 406 deaths, TC was inversely associated with mortality
from respiratory and gastrointestinal diseases, most of
which are of an infectious origin.29 It is unlikely that
these diseases caused the low TC, because the associa-
tions remained after the exclusion of deaths occurring
during the ﬁrst 5 years. In a study by Iribarren et al,
more than 100 000 healthy individuals were followed for
15 years. At follow-up, those whose initial cholesterol
level was lowest at the start had been hospitalised signiﬁ-
cantly more often because of an infectious disease that
occurred later during the 15-year follow-up period.30
This study provides strong evidence that low cholesterol,
recorded at a time when these people were healthy,
could not have been caused by a disease they had not
yet encountered.
Another explanation for an inverse association between
LDL-C and mortality is that high cholesterol, and there-
fore high LDL-C, may protect against cancer. The reason
may be that many cancer types are caused by viruses.31
Nine cohort studies including more than 140 000 indivi-
duals followed for 10–30 years have found an inverse asso-
ciation between cancer and TC measured at the start of
the study, even after excluding deaths that occurred
during the ﬁrst 4 years.32 Furthermore, cholesterol-
lowering experiments on rodents have resulted in
cancer,33 and in several case–control studies of patients
with cancer and controls matched for age and sex, signiﬁ-
cantly more patients with cancer have been on
cholesterol-lowering treatment.32 In agreement with
these ﬁndings, cancer mortality is signiﬁcantly lower in
individuals with familial hypercholesterolaemia.34
That high LDL-C may be protective is in accordance
with the ﬁnding that LDL-C is lower than normal in
patients with acute myocardial infarction. This has been
documented repeatedly without a reasonable explan-
ation.35–37 In one of the studies,37 the authors con-
cluded that LDL-C evidently should be lowered even
more, but at a follow-up 3 years later mortality was twice
as high among those whose LDL-C had been lowered
the most compared with those whose cholesterol was
unchanged or lowered only a little. If high LDL-C were
the cause, the effect should have been the opposite.
CONCLUSIONS
Our review provides the ﬁrst comprehensive analysis
of the literature about the association between LDL-C
and mortality in the elderly. Since the main goal of
prevention of disease is prolongation of life, all-cause
mortality is the most important outcome, and is also
the most easily deﬁned outcome and least subject to
bias. The cholesterol hypothesis predicts that LDL-C
will be associated with increased all-cause and CV mor-
tality. Our review has shown either a lack of an associ-
ation or an inverse association between LDL-C and
both all-cause and CV mortality. The cholesterol
hypothesis seems to be in conﬂict with most of
Bradford Hill’s criteria for causation, because of its
lack of consistency, biological gradient and coherence.
Our review provides the basis for more research about
the cause of atherosclerosis and CVD and also for a
re-evaluation of the guidelines for cardiovascular pre-
vention, in particular because the beneﬁts from statin
treatment have been exaggerated.38–40
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